All the terms that have this symbol (*) and are written in italics are explained further in our RBDCOV glossary. Take a look here:
Clinical trials against variants of COVID-19
The RBDCOV project includes clinical trials* that aim to test how efficient, tolerable and safe, the HIPRA vaccine for COVID-19. The vaccine being developed by HIPRA is an adjuvanted recombinant protein vaccine*, based on a receptor binding domain* (RBD) fusion heterodimer against SARS-CoV-2.
COVID-19 has been categorised by the WHO as a pandemic. Apart from it being a global health crisis, some of the containment measures adopted by different countries have incurred inevitable socio-economic implications.
The purpose behind the RBDCOV project is to offer a new tool towards controlling the pandemic for the short, medium and long term, and to manufacture and test the first recombinant protein-based vaccine* that may be authorised in Europe.
RBDCOV aims to generate robust data to demonstrate the safety and immunogenicity* of this vaccine given as a booster* vaccination to induce a higher and more durable immune response*, for potential new variants.
The project will benefit from the partners experiences and expertise in different areas and will contribute to the following significant advancements to face potential challenges associated with COVID vaccination:
